Up to 20 injectable cancer drugs will be made at
facilities in Taiwan and Germany under terms of a partnership between Baxter
and Scinopharm.
Baxter International and ScinoPharm Taiwan announced a
strategic partnership yesterday to develop, manufacture and commercialise an
initial five oncology drugs, with scope for an additional 15 injectable
molecules.
“The collaboration with ScinoPharm represents a rare
and compelling opportunity to partner with one of the world’s leading active
pharmaceutical ingredient [API] manufacturers with a 17-year history of quality
and safety serving the global pharmaceutical industry,” a spokesperson from
Baxter told in-Pharmatechnologist.com.
“Current branded sales of the initial five products
included in this partnership total more than $4bn annually. Baxter is not
disclosing specific cost details associated with this partnership.”
Manufacturing
Manufacturing will be carried out at both Baxter’s
facility in Halle, Germany and Scinopharm’s injectable plant in Tainan, Taiwan.
A Scinopharm spokesperson added the latter will be
ready for registration batch production by 2017, with the first in-house ANDA
submission from the partnership set for 2018, and a subsequent US FDA
inspection approval expected in 2019.
“ScinoPharm will be responsible for raw material
sourcing for all APIs and the injectables made in-house by ourselves,”
Scinopharm told us. “Baxter will be responsible for raw material sourcing for
the injectables made by themselves.”
Scinopharm invested NT$1.1bn ($36m) into its Tainan
site in 2012 to build a high potency cytotoxic injectable plant, and as such
does not need to add new capacity or staff to service this collaboration, we
were told.
By Dan Stanton
0 comentários:
Postar um comentário